How Should We Interpret Korea's Cancer Incidence and Survival Rates Heading Into 2026?

There is no nationwide statistic on "incidence rate" in the available notes for your question, but the 5-year relative survival rates by cancer type from Korea's National Cancer Registration Statistics give a good sense of the overall level of cancer treatment outcomes in Korea. These figures represent statistics for the entire country, not any single hospital.

Key Takeaways

• For 2019–2023, the combined 5-year relative survival rate for all cancers in Korea is 73.7% (National Cancer Registration Statistics 2019–2023, Korea Central Cancer Registry, National Cancer Center Korea).
• Rates vary widely by cancer type: thyroid cancer 100.2%, breast cancer 94.7%, stomach cancer 78.6%, lung cancer 42.5%, and leukemia 55.7% (National Cancer Registration Statistics 2019–2023).
• By comparison, U.S. SEER (2016–2022) figures are 91.9% for breast cancer, 39.8% for stomach cancer, 29.5% for lung and bronchus cancer, 68.6% for leukemia, and 98.3% for thyroid cancer.
• The gap between Korean and U.S. figures reflects not only treatment technology but also how early cancers are detected through national screening. In Korea, national screening includes gastroscopy and mammography every two years starting at age 40.
• All of these figures are population averages and are not meant to predict any individual's outcome.

How many cancer cases are diagnosed in Korea?

• There is no total figure for annual cases across all cancer types in the available notes, but annual diagnosis counts for individual cancer types are available. In 2023 alone, about 30,000 breast cancer cases and more than 35,000 thyroid cancer cases were diagnosed (National Cancer Registration Statistics).
• One reason thyroid cancer is diagnosed so frequently is that ultrasound testing is common, which leads to a high detection rate even for small tumors. As a result, clear criteria have been established for deciding between immediate surgery and active surveillance.
• Since overall incidence rates (new diagnoses relative to population) are not available in these notes, this article instead explains the situation using diagnosis counts and survival rates by cancer type.

Why is there such a big difference in survival rates between cancer types?

• For lung cancer, the 5-year relative survival rate rose by 30 percentage points compared with patients diagnosed in 1993–1995, reaching 42.5% (National Cancer Registration Statistics 2019–2023). This is attributed to increased early detection through national low-dose CT screening, as well as targeted therapies tailored to markers such as EGFR and ALK, and immune checkpoint inhibitors that have changed the course of advanced disease.
• A thyroid cancer survival rate above 100% means survival is no different from that of the general population of the same age, reflecting the generally favorable course of papillary and follicular carcinoma, which make up the majority of cases. However, medullary and anaplastic thyroid cancers follow an entirely different course.
• For leukemia, Korea's rate of 55.7% appears lower than the U.S. rate of 68.6%, but simple comparison is difficult because the composition of leukemia cases (the ratio of acute to chronic types and the age distribution at diagnosis) differs between the two countries.

FAQ — Is Korea's higher survival rate due to superior treatment?

It's not just about treatment technology — how early cancer is detected plays a major role. Because Korea runs national screening programs offering gastroscopy and mammography every two years from age 40, a relatively high proportion of stomach and breast cancers are caught at an early stage. Differences in national statistics should not be directly translated into predictions for an individual's outcome.

FAQ — Whose results do these survival rates represent?

These are national statistics for Korea as a whole, not the results of any specific hospital (National Cancer Registration Statistics 2019–2023). Korean medical law restricts the use of individual hospital outcome data in advertising, and actual treatment outcomes vary significantly from person to person depending on cancer stage, subtype, and overall health status.

Sources and Notes

• This article is based on National Cancer Registration Statistics (2019–2023, National Cancer Center Korea) and SEER (2016–2022) data referenced in notes on breast cancer, stomach cancer, hematologic cancers, thyroid cancer, lung cancer, and frequently asked questions.
• This content is provided for general medical information purposes only. Diagnosis and treatment methods, as well as outcomes, may vary depending on individual circumstances. Please consult with a medical professional to determine an accurate diagnosis and treatment plan.